Medical Condition News

RSS

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline's Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication.

4 Dec 2009

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

A coalition of cancer patient advocacy organizations led by the International Myeloma Foundation (IMF) and the MDS Foundation (MDSF), will bring its cancer patient “Statement of Principles” to the 2009 Meeting of the American Society of Hematology (ASH) in New Orleans December 5th through 8th.

4 Dec 2009

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Results from a new study showed patients with type 2 diabetes who also had coronary artery disease (CAD) experienced greater antiplatelet activity with the investigational antiplatelet drug prasugrel compared to Plavix(R) (clopidogrel). Patients who received a 60 mg loading dose and 10 mg maintenance dose of prasugrel achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix.

4 Dec 2009

Research study investigates how music therapy can help mentally ill children and young people

Queen's University Belfast is to play a major role in the biggest trial ever conducted to investigate how music therapy can help children and young people with severe mental health problems.

4 Dec 2009

Detroit Science Center launches "Diabetes: A Deeper Look" traveling exhibit

In the United States, a person is diagnosed with diabetes every 21 seconds. On December 5, 2009, the Detroit Science Center will debut its newest exhibit, Diabetes: A Deeper Look, to help answer questions that the public might have about diabetes, diabetes treatment and the role insulin plays in the body.

4 Dec 2009

Research study shows usage of stem cell-based therapies for treating age-related macular degeneration

An international team of scientists has rescued visual function in laboratory rats with eye disease by using cells similar to stem cells. The research shows the potential for stem cell-based therapies to treat age-related macular degeneration in humans.

4 Dec 2009

Risk of having a potentially fatal blood clot after surgery is higher, finds research

The risk of having a potentially fatal blood clot after surgery is higher and lasts for longer than had previously been thought, concludes new research published on bmj.com today.

4 Dec 2009

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

St. Jude Medical, Inc. today announced U.S. Food and Drug Administration (FDA) approval of its next-generation MultiSteering Technology software for Rapid Programmer™, a programming platform used to optimize neurostimulation therapy for chronic pain patients.

4 Dec 2009

CEBP journal emphasizes on the most up-to-date research of tobacco use

The study of tobacco has been the life-long focus of his research and now, Peter Shields, MD, deputy director of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, has led the effort to edit a special-edition of Cancer Epidemiology, Biomarkers & Prevention (CEBP) dedicated to best research practices in tobacco science from researchers the world over.

4 Dec 2009

Minimally invasive spine surgery poised for rapid growth

Minimally invasive techniques have become standard for many procedures, from the removal of the gallbladder to angioplasty, but the approach is now only beginning to be available to patients with spinal conditions. The surgical team at NewYork-Presbyterian Hospital/Columbia University Medical Center's Spine Center aims to bring the benefits of minimally invasive surgery for patients with intractable back pain, stenosis, spinal deformity, even spinal cancer.

4 Dec 2009

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is important for the recruitment of white blood cells into the atherosclerotic plaque.

4 Dec 2009

Health leaders to discuss latest breast cancer findings at CTRC-AACR San Antonio Breast Cancer Symposium

Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal of eradicating breast cancer.

4 Dec 2009

Scientists discover mechanism by which E6 oncoprotein of high-risk HPV16 promotes carcinogenesis

In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to degenerate. It is known today that the main culprits are viral proteins E6 and E7. Both proteins switch off different cellular control functions, thus promoting cell growth.

4 Dec 2009

Viral Genetics to develop drug therapies for immune-related disorders and diseases

The University of Colorado and Viral Genetics Inc., recently executed an exclusive license agreement that expands on its previous agreement allowing Viral Genetics to develop treatments for autoimmune diseases, graft rejection, HIV, and cancer based on the work of M. Karen Newell, Ph.D., a professor of biology at the University of Colorado at Colorado Springs.

4 Dec 2009

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced the completion of all planned surgeries in an ongoing Phase 2 clinical trial of the company’s gene transfer approach to the treatment of advanced Parkinson’s disease.

4 Dec 2009

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.

4 Dec 2009

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Kyto Biopharma Inc., is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.

4 Dec 2009

Pfizer announces a $9M cancer research collaboration in British Columbia

Pfizer is entering into a three-year, $9-million research collaboration with the BC Cancer Agency and the Vancouver Prostate Centre, a University of British Columbia (UBC) and Vancouver General Hospital (VGH) Centre of Excellence, to tackle new treatment avenues for breast, ovarian and prostate cancer. This is the single-largest investment by Pfizer into British Columbia's public research sector, and it recognizes the strength and world-class cancer expertise that resides in this province.

4 Dec 2009

Cannabis can reduce spasticity in MS patients

Cannabis can reduce spasticity in multiple sclerosis (MS) patients. A systematic review, published in the open access journal BMC Neurology, found that five out six randomized controlled trials reported a reduction in spasticity and an improvement in mobility.

4 Dec 2009

LCA-MA 2009 Report Card on Lung Cancer released

Today, Lung Cancer Alliance-Massachusetts (LCA-MA) issued its 3rd Annual Report Card on Lung Cancer. The 2009 Report Card is an assessment of progress being made against this lethal disease in the state of Massachusetts.

4 Dec 2009

Medical Condition News

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Research study investigates how music therapy can help mentally ill children and young people

Detroit Science Center launches "Diabetes: A Deeper Look" traveling exhibit

Research study shows usage of stem cell-based therapies for treating age-related macular degeneration

Risk of having a potentially fatal blood clot after surgery is higher, finds research

FDA approves St. Jude Medical's MultiSteering Technology software for optimizing neurostimulation therapy

CEBP journal emphasizes on the most up-to-date research of tobacco use

Minimally invasive spine surgery poised for rapid growth

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

Health leaders to discuss latest breast cancer findings at CTRC-AACR San Antonio Breast Cancer Symposium

Scientists discover mechanism by which E6 oncoprotein of high-risk HPV16 promotes carcinogenesis

Viral Genetics to develop drug therapies for immune-related disorders and diseases

Neurologix completes Phase 2 clinical trial of Parkinson’s study

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Kyto advancing with a program for humanization of the mAbTCR23 antibody

Pfizer announces a $9M cancer research collaboration in British Columbia

Cannabis can reduce spasticity in MS patients

LCA-MA 2009 Report Card on Lung Cancer released

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News